Stockholders’ Equity (Tables)
|
9 Months Ended |
Sep. 30, 2021 |
Stockholders' Equity Note [Abstract] |
|
Schedule of warrant and stock option grants with time-based vesting |
|
|
Warrant Grants |
|
|
Stock Option Grants |
|
|
Restricted Stock Units |
|
|
|
Number of shares subject to warrants |
|
|
Weighted- average exercise price per share |
|
|
Number of shares subject to options |
|
|
Weighted- average exercise price per share |
|
|
Number of shares subject to restricted stock units |
|
Balance at December 31, 2020 |
|
|
672,459 |
|
|
$ |
8.09 |
|
|
|
118,388 |
|
|
$ |
3.25 |
|
|
|
2,301,053 |
|
Granted |
|
|
389,344 |
|
|
|
2.30 |
|
|
|
- |
|
|
|
- |
|
|
|
843,338 |
|
Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(675,219 |
) |
Expired |
|
|
(11,699 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(150,833 |
) |
Balance at September 30, 2021 |
|
|
1,050,104 |
|
|
$ |
2.57 |
|
|
|
118,388 |
|
|
$ |
3.25 |
|
|
|
2,318,339 |
|
Exercisable at September 30, 2021 |
|
|
1,050,104 |
|
|
$ |
2.57 |
|
|
|
118,388 |
|
|
$ |
3.25 |
|
|
|
1,464,631 |
|
|
Schedule of fair value of the warrants as of original issuance date |
|
|
Issuance date |
|
Risk-free interest rate |
|
|
0.49 - 0.88 |
% |
Expected dividend yield |
|
|
- |
% |
Expected volatility |
|
|
100 |
% |
Term |
|
|
5 years |
|
Fair value of common stock |
|
|
1.95 - 2.24 |
|
|
Schedule of company’s outstanding warrants and options |
Warrants Outstanding |
|
|
Warrants Exercisable |
|
Exercise Price
Range |
|
|
Number Outstanding |
|
|
Weighted Average
Remaining
Contractual Life
(in years) |
|
|
Weighted Average
Exercise Price |
|
|
Number Exercisable |
|
|
Weighted Average
Exercise Price |
|
|
Intrinsic Value |
|
$ |
1.79 - $20.90 |
|
|
|
1,050,104 |
|
|
|
3.23 |
|
|
$ |
2.57 |
|
|
1,050,104 |
|
|
$ |
2.57 |
|
|
|
290,525 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding |
|
|
Options Exercisable |
|
Exercise Price
Range |
|
|
Number Outstanding |
|
|
Weighted Average
Remaining
Contractual Life
(in years) |
|
|
Weighted Average
Exercise Price |
|
|
Number Exercisable |
|
|
Weighted Average
Exercise Price |
|
|
Intrinsic Value |
|
$ |
2.64 - $28.50 |
|
|
|
118,388 |
|
|
|
2.94 |
|
|
$ |
3.25 |
|
|
118,388 |
|
|
$ |
3.25 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of stock-based compensation expense |
|
|
For the
three months ended |
|
|
For the
nine months ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Stock-based compensation expense |
|
$ |
699,084 |
|
|
$ |
488,304 |
|
|
$ |
1,929,446 |
|
|
$ |
2,844,851 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of stock-based compensation expense categorized by the equity components |
|
|
For the three months ended |
|
|
For the nine months ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Common stock |
|
$ |
699,084 |
|
|
$ |
488,304 |
|
|
$ |
1,929,446 |
|
|
$ |
2,844,851 |
|
Total |
|
$ |
699,084 |
|
|
$ |
488,304 |
|
|
$ |
1,929,446 |
|
|
$ |
2,844,851 |
|
|